AN2 Therapeutics (ANTX)
(Delayed Data from NSDQ)
$1.39 USD
+0.01 (0.72%)
Updated Jan 2, 2025 04:00 PM ET
After-Market: $1.40 +0.01 (0.72%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
AN2 Therapeutics, Inc. (ANTX) Price Targets
| Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
|---|---|---|---|
| $2.67 | $5.00 | $1.00 | 93.48% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for AN2 Therapeutics, Inc. comes to $2.67. The forecasts range from a low of $1.00 to a high of $5.00. The average price target represents an increase of 93.48% from the last closing price of $1.38.
Analyst Price Targets (3 )
Find the top stocks with the greatest price target potential and Zacks Rank of 1 or 2
Broker Rating
AN2 Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 3.00 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, one is Strong Buy, representing 20% of all recommendations. A month ago, Strong Buy represented 20%.
Broker Rating Breakdown
Brokerage Recommendations
| Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 |
| ABR | 3.00 | 3.00 | 3.00 | 2.60 | 2.60 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
| Date | Brokerage Firm | Analyst | Previous | Current |
|---|---|---|---|---|
| 11/20/2024 | SVB Securities | Joseph P Schwartz | Hold | Hold |
| 11/19/2024 | JMP Securities | Roy Buchanan | Strong Buy | Strong Buy |
| 11/18/2024 | Cowen & Co. | Ritu S Baral | Strong Buy | Hold |
| 8/13/2024 | Not Identified | Not Identified | Hold | Hold |
| 8/9/2024 | Evercore Partners | Liisa A Bayko | Hold | Strong Sell |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
| Current ABR | 3.00 |
| ABR (Last week) | 3.00 |
| # of Recs in ABR | 5 |
| Average Target Price | $2.67 |
| LT Growth Rate | NA |
| Industry | Medical - Biomedical and Genetics |
| Industry Rank by ABR | 68 of 251 |
| Current Quarter EPS Est: | -0.23 |
ANTX FAQs
AN2 Therapeutics, Inc. (ANTX) currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 5 brokerage firms.
The average price target for AN2 Therapeutics, Inc. (ANTX) is $2.67. The current on short-term price targets is based on 2 reports.
The forecasts for AN2 Therapeutics, Inc. (ANTX) range from a low of $1 to a high of $5. The average price target represents a increase of $93.48 from the last closing price of $1.38.
The current UPSIDE for AN2 Therapeutics, Inc. (ANTX) is 93.48%
Based on short-term price targets offered by three analysts, the average price target for AN2 Therapeutics, Inc. comes to $2.67. The forecasts range from a low of $1.00 to a high of $5.00. The average price target represents an increase of 93.48% from the last closing price of $1.38.